These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31182717)

  • 1. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.
    Jones GG; Del Río IB; Sari S; Sekerim A; Young LC; Hartig N; Areso Zubiaur I; El-Bahrawy MA; Hynds RE; Lei W; Molina-Arcas M; Downward J; Rodriguez-Viciana P
    Nat Commun; 2019 Jun; 10(1):2532. PubMed ID: 31182717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics.
    Boned Del Río I; Young LC; Sari S; Jones GG; Ringham-Terry B; Hartig N; Rejnowicz E; Lei W; Bhamra A; Surinova S; Rodriguez-Viciana P
    Proc Natl Acad Sci U S A; 2019 Jul; 116(27):13330-13339. PubMed ID: 31213532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis.
    Young LC; Hartig N; Boned Del Río I; Sari S; Ringham-Terry B; Wainwright JR; Jones GG; McCormick F; Rodriguez-Viciana P
    Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10576-E10585. PubMed ID: 30348783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An MRAS, SHOC2, and SCRIB complex coordinates ERK pathway activation with polarity and tumorigenic growth.
    Young LC; Hartig N; Muñoz-Alegre M; Oses-Prieto JA; Durdu S; Bender S; Vijayakumar V; Vietri Rudan M; Gewinner C; Henderson S; Jathoul AP; Ghatrora R; Lythgoe MF; Burlingame AL; Rodriguez-Viciana P
    Mol Cell; 2013 Dec; 52(5):679-92. PubMed ID: 24211266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of the SHOC2-MRAS-PP1C complex provides insights into RAF activation and Noonan syndrome.
    Bonsor DA; Alexander P; Snead K; Hartig N; Drew M; Messing S; Finci LI; Nissley DV; McCormick F; Esposito D; Rodriguez-Viciana P; Stephen AG; Simanshu DK
    Nat Struct Mol Biol; 2022 Oct; 29(10):966-977. PubMed ID: 36175670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
    Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
    Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS
    Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
    Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
    Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
    Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The scaffold protein Shoc2/SUR-8 accelerates the interaction of Ras and Raf.
    Matsunaga-Udagawa R; Fujita Y; Yoshiki S; Terai K; Kamioka Y; Kiyokawa E; Yugi K; Aoki K; Matsuda M
    J Biol Chem; 2010 Mar; 285(10):7818-26. PubMed ID: 20051520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.
    Sulahian R; Kwon JJ; Walsh KH; Pailler E; Bosse TL; Thaker M; Almanza D; Dempster JM; Pan J; Piccioni F; Dumont N; Gonzalez A; Rennhack J; Nabet B; Bachman JA; Goodale A; Lee Y; Bagul M; Liao R; Navarro A; Yuan TL; Ng RWS; Raghavan S; Gray NS; Tsherniak A; Vazquez F; Root DE; Firestone AJ; Settleman J; Hahn WC; Aguirre AJ
    Cell Rep; 2019 Oct; 29(1):118-134.e8. PubMed ID: 31577942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors.
    Lai LP; Fer N; Burgan W; Wall VE; Xu B; Soppet D; Esposito D; Nissley DV; McCormick F
    Proc Natl Acad Sci U S A; 2022 Feb; 119(5):. PubMed ID: 35091470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.
    Hata AN; Yeo A; Faber AC; Lifshits E; Chen Z; Cheng KA; Walton Z; Sarosiek KA; Letai A; Heist RS; Mino-Kenudson M; Wong KK; Engelman JA
    Cancer Res; 2014 Jun; 74(11):3146-56. PubMed ID: 24675361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of the MRAS-SHOC2-PP1C phosphatase complex.
    Hauseman ZJ; Fodor M; Dhembi A; Viscomi J; Egli D; Bleu M; Katz S; Park E; Jang DM; Porter KA; Meili F; Guo H; Kerr G; Mollé S; Velez-Vega C; Beyer KS; Galli GG; Maira SM; Stams T; Clark K; Eck MJ; Tordella L; Thoma CR; King DA
    Nature; 2022 Sep; 609(7926):416-423. PubMed ID: 35830882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.
    Rukhlenko OS; Khorsand F; Krstic A; Rozanc J; Alexopoulos LG; Rauch N; Erickson KE; Hlavacek WS; Posner RG; Gómez-Coca S; Rosta E; Fitzgibbon C; Matallanas D; Rauch J; Kolch W; Kholodenko BN
    Cell Syst; 2018 Aug; 7(2):161-179.e14. PubMed ID: 30007540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.
    Martinelli E; Morgillo F; Troiani T; Ciardiello F
    Cancer Treat Rev; 2017 Feb; 53():61-69. PubMed ID: 28073102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for SHOC2 modulation of RAS signalling.
    Liau NPD; Johnson MC; Izadi S; Gerosa L; Hammel M; Bruning JM; Wendorff TJ; Phung W; Hymowitz SG; Sudhamsu J
    Nature; 2022 Sep; 609(7926):400-407. PubMed ID: 35768504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
    Komatsu N; Fujita Y; Matsuda M; Aoki K
    Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.
    Kim SM; Kim H; Jang KW; Kim MH; Sohn J; Yun MR; Kang HN; Kang CW; Kim HR; Lim SM; Moon YW; Kim JH; Paik S; Cho BC
    Mol Cancer Ther; 2016 Jul; 15(7):1627-36. PubMed ID: 27196768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.
    Adamopoulos C; Papavassiliou KA; Poulikakos PI; Papavassiliou AG
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.